The Markers Core will serve as a resource for the development and optimization of established as well as new methods for measuring research endpoints in the individual projects. In conjunction with the Human Tissue Procurement Service and the Biometry Cores, the Markers Core will develop and implement appropriate sample collection, tracking, storage and preparation procedures for human material collected during the course of this proposal. It is essential that biological samples be collected and stored appropriately to achieve good quality assay results. The Markers Core will serve as a resource for assay development, analysis and quantitation of immunohistochemical procedures in support of each project. Endpoints will include markers of cell proliferation, apoptosis, as well as potential prognostic and/or predictive factors under evaluation in the SPORE proposal. The prognostic and/or predictive factors will Include assays for genetic variability (Project 1) COX-2 and NOS2 (Project 2), MUC-1 (Project 3), thioredoxin (Project 4) and c-myc (Project 5). The Tissue Service will be essential to the Markers Core for pathologic assessment of GI tissues and for obtaining tissue sections required for assays. The Markers Core will also work closely with the Biometry Core to maintain and evaluate quality control measures. Quality control measures will be an important component of the Markers Core and will be established for each assay. Historically, the Core has done a ten percent repeat of study samples to assess reproducibility.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA095060-01
Application #
6666182
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-05
Project End
2007-03-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85722
Goldenberg, Joshua M; Pagel, Mark D; Cárdenas-Rodríguez, Julio (2018) Characterization of D-maltose as a T2 -exchange contrast agent for dynamic contrast-enhanced MRI. Magn Reson Med 80:1158-1164
Jones, Kyle M; Pollard, Alyssa C; Pagel, Mark D (2018) Clinical applications of chemical exchange saturation transfer (CEST) MRI. J Magn Reson Imaging 47:11-27
Goldenberg, Joshua M; Cárdenas-Rodríguez, Julio; Pagel, Mark D (2018) Preliminary Results that Assess Metformin Treatment in a Preclinical Model of Pancreatic Cancer Using Simultaneous [18F]FDG PET and acidoCEST MRI. Mol Imaging Biol 20:575-583
Daryaei, Iman; Randtke, Edward A; Pagel, Mark D (2017) A biomarker-responsive T2exMRI contrast agent. Magn Reson Med 77:1665-1670
Daryaei, Iman; Jones, Kyle M; Pagel, Mark D (2017) Detection of DT-diaphorase Enzyme with a ParaCEST MRI Contrast Agent. Chemistry 23:6514-6517
Shkreta, Lulzim; Blanchette, Marco; Toutant, Johanne et al. (2017) Modulation of the splicing regulatory function of SRSF10 by a novel compound that impairs HIV-1 replication. Nucleic Acids Res 45:4051-4067
Kurzius-Spencer, Margaret; Harris, Robin B; Hartz, Vern et al. (2016) Relation of dietary inorganic arsenic to serum matrix metalloproteinase-9 (MMP-9) at different threshold concentrations of tap water arsenic. J Expo Sci Environ Epidemiol 26:445-51
Tsikitis, Vassiliki L; Potter, Amiee; Mori, Motomi et al. (2016) MicroRNA Signatures of Colonic Polyps on Screening and Histology. Cancer Prev Res (Phila) 9:942-949
Hingorani, Dina V; Montano, Luis A; Randtke, Edward A et al. (2016) A single diamagnetic catalyCEST MRI contrast agent that detects cathepsin B enzyme activity by using a ratio of two CEST signals. Contrast Media Mol Imaging 11:130-8
Fernández-Cuervo, Gabriela; Sinharay, Sanhita; Pagel, Mark D (2016) A CatalyCEST MRI Contrast Agent that Can Simultaneously Detect Two Enzyme Activities. Chembiochem 17:383-7

Showing the most recent 10 out of 239 publications